A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting

被引:88
作者
Candiotti, Keith A. [1 ,2 ]
Kovac, Anthony L. [3 ]
Melson, Timothy I. [4 ]
Clerici, Giuseppina [5 ]
Gan, Tong Joo [6 ]
机构
[1] Univ Miami, Dept Anesthesiol, Miami, FL USA
[2] Univ Miami, Dept Perioperat Med & Pain Management, Miami, FL USA
[3] Univ Kansas, Med Ctr, Dept Anesthesiol, Kansas City, KS 66103 USA
[4] Helen Keller Mem Hosp, Sheffield, AL USA
[5] Helsinn Healthcare SA, Dept Res & Dev, Lugano, Switzerland
[6] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA
关键词
D O I
10.1213/ane.0b013e31817b5ebb
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
BACKGROUND: In this randomized, double-blind Study we assessed the efficacy and safety of three different doses of the 5-HT, receptor antagonist palonosetron, compared with placebo, on the incidence and severity of postoperative nausea and vomiting (PONV) for 72 h postsurgery. METHODS: Five hundred seventy-four patients undergoing either outpatient abdominal or gynecological laparoscopic surgery were stratified according to gender, history of PONV or motion sickness, and nonsmoking status. Patients with >= 2 PONV risk factors were eligible and randomized to receive one of three doses of IV palonosetron (0.025 mg, 0.050 mg, or 0.075 mg) or placebo immediately prior to induction of anesthesia. Co-primary efficacy end-points included complete response (CR: no emetic episodes and no rescue medication) during the 0 to 24 h and 24 to 72 h postoperative time intervals. RESULTS: A close-response trend in the proportion of patients with a CR was observed with increasing doses of palonosetron in the first 24 hrs. CR rates for placebo and palonosetron 0.075 mg were 26%, and 43%, respectively, for the 0 to 24 h postoperative interval (P = 0.004), and 41% and 49%,, respectively, for the 24 to 72 h interval (P = 0.188). Compared with placebo, palonosetron 0.075 mg was associated with a significant downward shift toward less intense nausea (P = 0.042) and with significant reduction in the impact of PONV on patient functioning (P 0.004) during the 0 to 24 h interval. CONCLUSIONS: A single 0.075-mg IV dose of palonosetron significantly increased the CR rate (no emetic episodes and no rescue medication) from 0 to 24 h, decreased nausea severity and patients experienced significantly less interference in their postoperative function due to PONV.
引用
收藏
页码:445 / 451
页数:7
相关论文
共 19 条
[1]  
Decker Georgia M, 2006, J Support Oncol, V4, P35
[2]   Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron [J].
Eisenberg, P ;
Figueroa-Vadillo, J ;
Zamora, R ;
Charu, V ;
Hajdenberg, J ;
Cartmell, A ;
Macciocchi, A ;
Grunberg, S .
CANCER, 2003, 98 (11) :2473-2482
[3]   Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting -: Are they all the same? [J].
Gan, TJ .
CNS DRUGS, 2005, 19 (03) :225-238
[4]   Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery [J].
Gan, TJ ;
Franiak, R ;
Reeves, J .
ANESTHESIA AND ANALGESIA, 2002, 94 (05) :1199-1200
[5]   Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [J].
Gralla, R ;
Lichinitser, M ;
Van der Vegt, S ;
Sleeboom, H ;
Mezger, J ;
Peschel, C ;
Tonini, G ;
Labianca, R ;
Macciocchi, A ;
Aapro, M .
ANNALS OF ONCOLOGY, 2003, 14 (10) :1570-1577
[6]  
Gupta A, 2003, ANESTHESIOLOGY, V99, P488
[7]   A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period [J].
Kovac, Anthony L. ;
Eberhart, Leopold ;
Kotarski, Jan ;
Clerici, Giuseppina ;
Apfel, Christian .
ANESTHESIA AND ANALGESIA, 2008, 107 (02) :439-444
[8]   PHARMACOLOGICAL PROPERTIES OF DOLASETRON, A POTENT AND SELECTIVE ANTAGONIST AT 5-HT3 RECEPTORS [J].
MILLER, RC ;
GALVAN, M ;
GITTOS, MW ;
VANGIERSBERGEN, PLM ;
MOSER, PC ;
FOZARD, JR .
DRUG DEVELOPMENT RESEARCH, 1993, 28 (01) :87-93
[9]  
Odom-Forren Jan, 2006, J Perianesth Nurs, V21, P411, DOI 10.1016/j.jopan.2006.09.001
[10]   Quality of life studies in chemotherapy-induced emesis [J].
Osoba, D ;
Zee, B ;
Warr, D ;
Kaizer, L ;
Latreille, J ;
Pater, J .
ONCOLOGY, 1996, 53 :92-95